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doi:10.1016/j.asjsur.2011.08.002Summary Background: The role of pelvic exenteration in locally advanced rectal cancer
(LARC) has not been clearly defined. This procedure carries a mortality rate of approximately
10%. The challenges during pelvic surgery are different between men and women. The
morbidity in men with LARC who received pelvic exenteration was analyzed.
Methods: Medical records of men with LARC undergoing total pelvic exenteration or supraleva-
tor pelvic exenteration from January 1991 to December 2007 were retrospectively reviewed.
Results: A total of 23 cases were included in the analysis. Thirteen patients had primary
cancer; 10 had recurrent cancer. Microscopically clear surgical margins were obtained in 14
patients (60.9%). Sixteen patients (69.6%) experienced major or minor postoperative complica-
tions. The overall in-hospital mortality rate was 8.7%. Ten patients (43.5%) died within 1 year
after surgery. All 10 patients with early mortality experienced refractory complications and
repeated surgeries. The longest survival of patients with margin involvement was 25 months.
The correlation between involved surgical margins and 1-year mortality was statistically signif-
icant (p Z 0.001).
Conclusion: Resection margins with tumor involvement after pelvic exenteration is associated
with poor prognosis and early mortality in men with locally advanced rectal cancer.
Copyright ª 2011, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.Colorectal Surgery, Depart-
neral Hospital, Number 160,
ung City, Taiwan.
(H.-M. Wang).
n Surgical Association. Published1. Introduction
Total pelvic exenteration was first described by Bruncshwig
in 1948.1 Numerous reports have been published in the
gynecologic literature that have confirmed the technicalby Elsevier Taiwan LLC. All rights reserved.
Table 1 Oncologic and surgical characteristics.
Number of patients (N Z 23), %
116 T.-W. Hsu et al.feasibility in treating squamous cell carcinomas of the
cervix.2,3 The role of pelvic exenteration in locally
advanced rectal cancer (LARC) has not been clearly
defined. It demands advanced surgical technique, and it is
sometimes difficult to obtain clear resection margins.4
Pelvic exenteration carries a mortality rate of about 10%,
and one-half of the patients experience significant mor-
bidity.4e9 Even though several reports have concluded that
pelvic exenteration is an effective treatment for LARC,5,6
this procedure is still not routinely performed in many
institutions.
Most reports regarding the surgical and oncologic
outcomes of pelvic exenteration for LARC did not focused
on patient sex.1,4e11 In our experience, the anatomy as well
as the surgical challenges of pelvic surgery is different
between men and women. The uterus and vagina in women
is located between the rectum and the urinary bladder, and
buffering from this tissue will delay invasion of the urinary
system. In men, aggressive cancers will directly invade the
urogenital organs such as the urinary bladder, seminal
vesicles, or prostate. In addition, men have a narrower
pelvic bone cage, and deeper lower rectum, which
increases the difficulty of surgical dissection and obtaining
satisfactory resection margins.
Various complications of pelvic exenteration have been
reported in the literature. The most common include bowel
obstruction, intra-abdominal or intrapelvic abscess forma-
tion, enterocutaneous fistula, ureteral fistula or obstruc-
tion, bowel perforation, anastomotic leakage, pneumonia,
deep venous thrombosis, and renal failure.5e8 These
complications are often life threatening, or significantly
compromise postoperative quality of life. In our experi-
ence, we found that a large percentage of patients expe-
rienced serious morbidities without significant benefit.
Some patients experienced prolonged, repeated hospitali-
zations before their death, while other patients had disease
control or cure. In this retrospective report, we analyzed
the morbidity and outcomes in men with LARC who
received pelvic exenteration.Tumor
Primary 13 (56.5)
Recurrent 10 (43.5)
Procedure
TPE 18 (78.3)
SLE 5 (21.7)
Tumor invasion
Urinary bladder 14 (60.9)
Prostate 8 (34.8)
Seminal vesicle 6 (26.1)
Pelvic wall 9 (39.1)
Ureter 2 (8.7)
Jejunum 1 (4.3)
Coccyx bone 1 (4.3)
Urine diversion
Ileal conduit 18 (78.3)
Ureterostomy 2 (8.7)
Ureteroureterostomy 3 (13.0)
SLE Z supralevator pelvic exenteration; TPE Z total pelvic
exenteration.2. Methods
All patients with LARC who underwent total pelvic exen-
teration (TPE) or supralevator pelvic exenteration (SLE)
from January 1991 to December 2007 were identified in the
database of Taichung Veterans General Hospital, and their
medical records were retrospectively reviewed. Women
diagnosed with squamous cell carcinoma, indicating
a different treatment policy, were excluded. TPE was
defined as the removal of the rectum, urinary bladder,
seminal vesicles, prostate, anus, and soft tissue within the
endopelvic fascia, and performing fecal and urine diver-
sion. SLE was defined as TPE without removal of the anal
sphincter and anus, which allows immediate or delayed
restoration of bowel continuity. The past histories, clinical
characteristics, pathologic reports, oncological outcomes,
complications, morbidities, and postoperative courses were
analyzed and summarized. Tumor invasions of radial
margins, adjacent organs, or resection lines were recorded.
Margin status was defined as: R0 resection, no tumor
involvement of the surgical margin; R1 resection,microscopic tumor invasion of the surgical margin; and R2
resection, gross tumor invasion of margin.
2.1. Statistical analyses
The survival was calculated using the Kaplan-Meier method.
Statistical significance was calculated with Fisher’s exact
test. Analyses were performed using the Statistical Package
for the Social Sciences (SPSS) software (SPSS Inc., Chicago,
IL, USA).
3. Results
During the period from January 1991 to December 2007, 27
patients diagnosed with LARC who received TPE or SLE were
identified. One patient was excluded due to a pathologic
diagnosis of squamous cell carcinoma. One woman was not
included in the analysis. Two patients were excluded
because there was only fibrotic and necrotic tissue without
evidence of tumor recurrence in the TPE surgical specimen.
Thus, a total of 23 men were eligible and included in the
analysis. The mean age at pelvic exenteration was 57.6
years (range, 36e82 years). Thirteen patients had primary
cancer, and 10 patients had recurrent cancer. Eight
patients with recurrent disease had experienced chemo-
therapy and radiotherapy before or after their previous
surgery. The average length of hospital stay (LOS) was 24.0
days (range, 6e85 days). The mean LOS of complicated and
uncomplicated cases was 32.0 and 16.8 days, respectively.
Three patients underwent combined procedures including
cholecystectomy, small bowel resection, liver resection for
metastasis, or removal of the coccyx in the same operation.
Fourteen patients accepted intravenous or oral chemo-
therapy after pelvic exenteration. Nine patients accepted
postoperative radiotherapy.
Figure 1 Kaplan-Meier survival curve.
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of surgery are summarized in Table 1. Eighteen patients
underwent TPE and five patients underwent SLE. The
methods of urine diversion included ileal conduit (78.3%),
bilateral ureterostomy (8.7%), and ureteroureterostomy
with a single opening (13.0%). Tumor invasion to levater ani
muscle or perianal skin was the indicator for performing
TPE. There was no significant difference in the pattern of
organ invasion between patients who underwent TPE and
SLE. The oncologic outcomes and patient survival are shown
in Table 2. The majority of patients (87.0%) were diagnosed
with moderately differentiated adenocarcinoma after
pathologic examination of the surgical specimen. Micro-
scopically clear surgical margins were obtained in only 14
patients (60.9%). Eight patients with R1 or R2 resections
and two patients with R0 resections, including a patient
with poorly differentiated adenocarcinoma, died within 1
year after surgery. The Kaplan-Meier survival curve is shown
in Fig. 1. Interestingly, none of the patients who survived
the first year died within the second year. One patient died
of brain metastasis 63 months after the surgery. Four
patients (17.4%) were disease-free after 10 years.
The postoperative courses of the patients were quite
diverse. Each patient experienced different combinations
of surgical complications, disease progression, tumor
relapse, and adverse effects of chemotherapy. The post-
operative complications are summarized in Table 3. Sixteen
patients (69.6%) experienced major or minor postoperative
complications. The most common complications wereTable 2 Patient outcomes and survival.
Number of patients (%) or survival
Tumor cell type
MDA 20 (87.0)
MA 1 (4.3)
LS 1 (4.3)
PDA 1 (4.3)
Resection margin
R0 14 (60.9)
R1 3 (13.0)
R2 6 (26.1)
DFS after R0 resection
Range 3e48 mo
Mean 19.6 mo
Median 20.0 mo
Overall survival All R0 resections
Median 25.0 mo 39.0 mo
1 y 13 (56.5) 12 (85.7)
2 y 13 (56.5) 12 (85.7)
3 y 8 (34.8) 8 (57.1)
5 y 5 (21.7) 5 (35.7)
10 y 4 (17.4) 4 (28.6)
DFS Z disease-free survival; LS Z leiomyosarcoma; MA Z
mucinous adenocarcinoma; MDA Z moderately differentiated
adenocarcinoma; PDA Z poorly differentiated adenocarci-
noma; R0 resection Z no tumor involvement of the surgical
margin; R1 resection Z microscopic tumor invasion of the
surgical margin; R2 resectionZ gross tumor invasion of margin.bowel obstruction (17.4%), wound infection (17.4%), and
pelvic abscess (17.4%). Two patients (8.7%) experienced
small bowel perforation induced by obstruction or stran-
gulation. Nine patients (39.1%), including all three patients
who received a ureteroureterostomy, experienced urinary
system complications. The overall in-hospital mortality rate
was 8.7%.
The postoperative courses and overall survival are
summarized in Table 4. One patient was lost to follow-up inTable 3 Postoperative complications.
Number of patients (%)
Urinary diversion complications
Urine leakage 2 (8.7)
Hydronephrosis 2 (8.7)
Renal stone 2 (8.7)
Urinary tract infection 2 (8.7)
Pyelonephritis 1 (4.3)
GI complications
Upper GI bleeding 2 (8.7)
Enterocutaneous fistula 1 (4.3)
Bowel obstruction 4 (17.4)
Bowel perforation 2 (8.7)
Wound complications
Infection 4 (17.4)
Dehiscence 1 (4.3)
Pelvic abscess 4 (17.4)
Respiratory failure 1 (4.3)
Hepatic failure 1 (4.3)
Sepsis 2 (8.7)
With complicationsa 16/23 (69.6)
Perioperative mortalityb 2/23 (8.7)
a Patients experienced at least one postoperative complication.
b Patients died without discharge from hospital after pelvic
exenteration.
GI Z gastrointestinal.
Table 4 Summary of postoperative courses and survival.
Date of
surgery
OS (mo) Age Invaded
organs
Margins Cause of
death
Postoperative course summary
2004.06 0.6 82 B, Ur R2 C Expired 18 d after surgery due to complications
2003.04 2.8 70 J, B, PW R2 C Prolonged hospital stay for 83 d before death
1992.09 4 63 B, PW R2 C, PD Died of PD and complications at 4 mo
2003.09 4 61 P, SV R2 C, PD Died of PD and complications at 4 mo
1994.09 6 45 P, LNs R2 C, PD Died of PD and complications at 6 mo
2007.01 6 60 P R1 C Died of complications of surgery and chemotherapy
2005.03 10 38 B, P, SV R2 PD Repeated resection for recurrent tumor until death
2003.09 10 47 B, SV R0 C Refractory bowel obstruction and malnutrition until death
2006.05 10 34 B, SV, J, Ur R1 PD Pre-existing lung metastasis, died of PD
2001.12 11 67 B R0 C Prolonged hospital stay for complications before death
1995.04 >25 63 B R0 Lost Lost to follow-up at 25 mo, terminal stage
2003.01 25 71 B, P, SV R1 PD Recurrence at 11 mo, died of disease
2007.05 >26 65 B, SV, P R0 Lost Multiple complications, lost to follow-up in stable condition
1993.07 28 67 PW R0 PD 20 mo of DFS after liver metastasis resection
1992.12 35 39 P, CB R0 PD CB removed, achieved 30 mo of DFS
1993.05 38 40 B R0 PD DFS 22 mo before local recurrence
1991.01 40 66 B, P R0 PD Local recurrence at 3 mo, but lived for 40 mo
1995.07 55 69 B R0 PD DFS 43 mo before lung metastasis
2004.06 63 50 B R0 PD DFS 14 mo before lung metastasis
1994.09 >120 40 B R0 No recurrence
1998.07 >120 75 B R0 No recurrence
1991.11 >120 57 B, PW R0 No recurrence
1992.11 >120 57 B, P R0 No recurrence
B Z urinary bladder; C Z complications; CB Z coccyx bone; DFS Z disease-free survival; J Z jejunum; LNs Z lymph nodes;
OS Z overall survival; P Z prostate; PD Z progressive disease; PW Z pelvic wall; SV Z seminal vesicle; Ur Z ureter.
118 T.-W. Hsu et al.the 26th month postoperatively; at that time, he was in
stable condition without disease recurrence. Another
patient was lost to follow-up 25 months after surgery; he
was in the terminal stage of disease and reportedly died.
Four patients were disease-free after 10 years of follow-up,
while 10 patients (43.5%) died within 1 year after surgery.
The shortest survival was 18 days after the surgery, and
death was due to postoperative complications. Another
patient had no chance to be discharged from the hospital
until he died 83 days after surgery due to repeated bowel
obstructions, leakages, and abscess formation. No patient
died within the second postoperative year.
Seven patients (30.4%) died within 6 months after
surgery due to surgical complications with or without
cancer progression. One patient died 10 months after
surgery due to repeated local recurrence and reoperations.
One patient with lung metastases that was diagnosed
preoperatively died of disease progression 10 months
postoperatively. All 10 patients with early mortality
(defined as survival <1 year) experienced refractory
complications, prolonged hospital stay, and repeated
salvage surgeries in their postoperative courses. All
mortalities that occurred more than 2 years after surgery
were due to disease relapse rather than surgical compli-
cations. Every patient with R2 resection margins died
within 10 months, and 83.3% of them died within 6 months.
The longest survival of patients with involved margins (R1
or R2) was 25 months; however, eight of them (88.9%) died
within 10 months. Fourteen patients had free surgical
margins (R0 resection). In this group, two patients died ofcomplications within 1 year. Eight of them died due to
disease relapse between 28 and 63 months postoperatively.
Four patients were disease-free after 10 years. The 2-year
survival of R0 patients was 85.7%. One patient who under-
went combined hepatectomy for liver metastasis had
a disease-free survival (DFS) of 20 months and overall
survival (OS) of 28 months. One patient who underwent
combined coccyx resection due to tumor invasion had a DFS
of 30 months and OS of 38 months.
The correlations between clinical factors and 1-year
mortality are presented in Table 5. The 1-year mortality
was relatively higher for those with recurrent disease
(60.0%); however, it was without statistical significance.
Elderly patients (>60 years old) did not have a higher
1-year mortality rate (46.2%). Tumor involvement of the
resection margins was a significant negative factor for
1-year survival (p Z 0.001). The occurrence of surgical
complications was not associated with an increase in 1-year
mortality.4. Discussion
Pelvic exenteration is a challenging surgical procedure, and
it has been used to treat LARC with different surgical
variations and combined with various modalities of
therapy.5e16 Because of the limited indications of pelvic
exenteration and high morbidity, large scale studies are
very rare. Yeung et al. reported 50 cases of TPE for LARC
with curative or palliative intent in 1993.8 In those 50 cases,
Table 5 Clinical factors and 1-year mortality.
Alive Death p
Margin
Positive 1 (7.7%) 8 (80%) 0.001
Negative 12 (92.3%) 2 (20%)
Surgery method
SLE 4 (30.8%) 1 (10%) 0.251
TPE 9 (69.2%) 9 (90%)
Primary tumor
Yes 9 (69.2%) 4 (40%) 0.164
No 4 (30.8%) 6 (60%)
Age > 60 y
Yes 7 (53.8%) 6 (60%) 0.552
No 6 (46.2%) 4 (40%)
Complications
Yes 8 (61.5%) 8 (80%) 0.313
No 5 (38.5%) 2 (20%)
TPE Z total pelvic exenteration; SLE Z supralevator pelvic
exenteration.
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rate was 14%, and the overall 5-year survival was 6%.
Alternatively, Gannon et al reported 72 cases of pelvic
exenteration for primary LARC.5 In this study, complications
occurred in 43% of the cases, and the 5-year DFS was 52%.
The authors concluded that an aggressive surgical approach
provides most patients 5-year DFS, and selected patients
with recurrent LARC will also benefit from pelvic exenter-
ation. Bannura et al studied 30 women with primary LARC
who underwent posterior pelvic exenteration (PPE), and
concluded that PPE prolonged operative time and increased
postoperative complications showed a trend toward poor
prognosis with respect to recurrence and survival.10 Ver-
maas et al treated 35 consecutive patients with primary or
recurrent LARC with preoperative external beam radiation
therapy, with or without intraoperative radiotherapy,
combined with TPE and achieved an 88% 5-year local control
rate and a 52% 5-year OS for primary cases.6 Ike et al studied
71 patients with primary T3 or T4 rectal cancer who
underwent curative TPE in Japan.12 The authors reported
a 66.2% complication rate and 51.4% 5-year survival.
Yamada et al reported 20 cases of LARC who underwent TPE
with sacral resection in 2002, and they concluded that
pelvic exenteration and sacral resection for primary or
recurrent rectal cancer are tolerable procedures with a low
mortality rate.15 Most published papers have focused on
survival and complication rates with different treatment
strategies. The morbidity of the patients with postoperative
complications had not been systemically reported. As shown
in Table 4, patients with complications had prolonged
hospitalizations, and most of these patients spent their
residual lives in the hospital. Considering the balance
between costs and benefits, we believe that there should be
more restricted indications of pelvic exenteration for LARC.
The cases analyzed in this report occurred over a range
of 17 years. Surgical instruments, chemotherapies, and
radiotherapies have evolved during this time interval. Atour institution, pelvic exenteration for LARC had never
been combined with IORT or local flaps. Radiotherapy was
reported to be beneficial for local tumor control without
improvement on overall survival for resectable rectal
cancer.17,18 Wiid reported in 2002 that preoperative radio-
therapy had a negative effect on pelvic exenteration.7 In
our series, patients did not accept preoperative chemo-
radiotherapy due to various reasons, including severe pain,
tumor obstruction, or previous radiotherapy. Nine of our
patients accepted postoperative radiotherapy because they
had better performance status and less surgical complica-
tions. Fourteen patients accepted different combinations
(including 5-fluorouracil, capecitabine, tegafur, irinotecan,
or oxaliplatin) and intervals of chemotherapies after pelvic
exenteration. The impact of chemotherapy in this study was
inaccessible due to complicated treatments and small
number of patients. In addition, postoperative chemo-
therapy or radiotherapy could only be started after patients
recovered from the surgery. Patients with postoperative
morbidities had less chance to gain benefit from adjuvant
chemoradiotherapy. In our study, pre-existing selection bias
had obscured the impact of chemoradiotherapy on patient
outcomes. Surgical complicationsdrather than chemo-
therapy or radiotherapydis the key factor for patient
survival in this study. The pelvic anatomy and organs
surrounding the rectum are different in males and females.
The patterns of local cancer invasion and surgical technical
difficulties are also different. As a tertiary center of
veterans, most of our patients are men. The man-to-woman
ratio who underwent pelvic exenteration was 26:1, and, by
excluding women, this analysis does not contain biases that
may be due to the anatomic differences between the sexes.
The 1-year mortality rate in our series was 43.5% (Table 5).
The tumor-involved surgical margin is a statistically signif-
icant factor (p Z 0.001). However, several subgroups of
patients do have a lower percentage of 1-year mortality,
including patients who underwent SLE (20.0%), primary
disease (30.8%), and patients who experienced no surgical
complications (28.6%). These factors were reported to have
better outcomes in many reports.4e6 Considering the small
total patient number in this study, the value of these
factors in predicting surgical outcomes should not be
underestimated. Recurrent disease had twice the risk of
1-year mortality compared with primary disease (60.0% vs.
30.8%). Although this factor did not reach statistical
significance (p Z 0.164), we still suggest that surgeons
should be more conservative in performing pelvic exen-
teration for recurrent cases.
In patients with R0 resection margins, 85.7% were alive
after 2 years. The 5-year survival was 35.7% in this curative
resection group. In addition, four of the patients (28.6%)
were disease-free after 10 years. These data are compa-
rable with those of other published reports.5e11 Curative
resection alone cured (defined as disease-free status after
10 years) more than one-fourth of our patients. However,
all patients with R2 margins died within 1 year due to
complications, with or without disease progression. In fact,
eight of the nine patients with R1 or R2 margins were dead
within 10 months. The survival of patients was significantly
influenced by the margin status in our patients.
Pelvic exenteration has been used as palliative surgery
by some authors.8,11 In our study, two of the patients with
120 T.-W. Hsu et al.surgical complications remained in the hospital until their
death. All of the six patients with R2 resection margins died
within 10 months. In addition, 83.3% of them had repeated
complications and disease progression before their death
within 6 months postoperatively. With only two exceptions,
all mortalities that occurred within 1 year after surgery
were related to complications. One patient had pre-
existing lung metastasis, and the other patient had poorly
differentiated adenocarcinoma and underwent three addi-
tional palliative debulking surgeries before he died. These
10 patients with early mortality gained nothing from the
surgery, except for suffering. Interestingly, all patients who
survived the first year lived at least 2 years. All of the seven
confirmed mortalities (two patients were lost to follow-up
and excluded) occurred more than 2 years after surgery
and were related to disease relapse rather than surgical
complications. At least four patients (perhaps 5 because 1
patient was lost to follow-up in the disease-free status)
enjoyed 10 years of disease-free survival. Based on these
data, the outcomes of the patients seem to be distributed
into two groups, with some patients dying early due to
complications and some experiencing good disease control
for many years.
Our explanation of this phenomenon is that pelvic
exenteration is a group of complicated surgeries that
includes organ resections, urinary diversion, multiple bowel
or urinary tract anastomosis, and stool diversion. The
removal of all tissues within the endopelvic fascia also
creates a large dead space that is prone to abscess
formation. In addition, local radiotherapy, when adminis-
tered, can interfere tissue healing. These factors, as well as
the advanced cancer, lead to a high rate of complications
with pelvic exenteration. In our experience, the morbidity
of pelvic exenteration is much more complicated and
devastating than that of low-anterior resection for rectal
cancer. One site of anastomosis leakage often induces the
breakdown of surrounding tissues and creates additional
leakage. In our series, complications after pelvic exenter-
ation often led to early mortality. In contrast, patients who
survived from potential surgical complications had an OS of
at least 2 years and a cure rate of 28.6%.
Considering the early mortality rate of the patients in
this study, the role of pelvic exenteration for LARC with
palliative intent is not justified. A debulking surgery for an
unresectable tumor will inevitably result in a positive
surgical margin, which is associated with a high early
mortality rate. The only patient in our study with pre-
existing lung metastasis died 10 months after pelvic exen-
teration due to disease progression. According to these
data, it is reasonable to suggest that pelvic exenteration
with palliative intent for LARC should not be performed. In
addition, pelvic exenteration should not be performed for
LARC if preoperative imaging studies suggest a high prob-
ability of positive resection margins.References
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